New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 16, 2014
16:53 EDTJNJFDA issues CRLs for Johnson & Johnson's sNDAs for use of Xarelto
On Friday morning, Johnson & Johnson unit Janssen Research & Development announced the U.S. Food and Drug Administration issued complete response letters, CRLs, regarding supplemental New Drug Applications, sNDAs, for the use of Xarelto, rivaroxaban, an oral anticoagulant, to reduce the risk of secondary cardiovascular events -- defined as heart attack, stroke or death -- in patients with acute coronary syndrome, ACS, and to reduce the risk of stent thrombosis in the same population, in combination with standard antiplatelet therapy. "We remain committed to providing patients who have suffered from acute coronary syndrome with additional protection against stent thrombosis and secondary life-threatening cardiovascular events," said Paul Burton, M.D., Ph.D., Vice President, Clinical Development, Janssen Research & Development. "We are evaluating the contents of the letters and will determine the appropriate next steps."
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
19:49 EDTJNJJohnson & Johnson to open shared services headquarters in Florida
Subscribe for More Information
August 25, 2015
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
09:03 EDTJNJAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
August 21, 2015
09:01 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.
August 20, 2015
11:33 EDTJNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use